WPD Pharmaceuticals’ WP1066 Drug Candidate Had Breakthrough Discovery
WD1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models
VANCOUVER, British Columbia, Feb. 10, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage
pharmaceutical company, is pleased to announce that its drug candidate WP1066 was the subject of a scientific paper published in 2019 entitled "Immunological Reprogramming in the CNS Tumor
Microenvironment and Therapeutic Efficacy of Radiotherapy with STAT3 Blockade” which found that drug candidate WP1066 is potentially capable of immune reprogramming in Glioblastoma animal
Currently in clinical trials at the University of Texas, MD Anderson Cancer Center, WP1066 represents a new class of drugs, which WPD identifies as “Immune/Transcription Modulators”. WP1066 and related analogs have not only demonstrated the ability to directly induce apoptosis (tumor cell death) but also the ability to stimulate an immune response to tumors allowing T-cells to attack tumor cells. These unique drug properties are a result of WP1066’s ability to inhibit the activated form of STAT3, (p-STAT3.
One of the key findings of the research is that immune-competent mice treated with both radiation and WP1066 developed an immunological memory that enabled them to prevent regrowth of the tumor after these tumor cells were reintroduced. The result was the development of long-term survivors, leading to an increase in overall survival in these models. Of note was that mice with a compromised immune system did not show this effect. The study was also showed the most robust immunological responses were located in the CNS (Central Nervous System) tumor microenvironment rather than peripheral non-tumor tissue. Importantly, the study indicated that the combination of STAT3 inhibition with whole brain radiotherapy had the capacity to enhance the therapeutic effect against established tumors based on immunological competence.
Mariusz Olejniczak, CEO of WPD commented “The findings in the report by Dr. Martina Ott, of MD Anderson Cancer Center in collaboration with Dr. Amy Heimberger (the Principle Investigator of the current investigator-initiated clinical of WP1066 for brain tumors) are very encouraging, especially given the increasing focus on the potential of STAT3 inhibition for the treatment of cancer. Making any kind of discovery in treating glioblastoma is exciting, and these findings could have a significant impact on understanding the role of STAT3 inhibition, as well as help focus our continued development of WP1066.”